Peter H. Wiernik • John M. Goldman
Janice P. Dutcher • Robert A. Kyle
Editors

2013

Fifth Edition

The fi fth edition of Neoplastic Diseases of the Blood is long overdue because tremendous progress in our understanding of the nature of hematologic malignancies and their treatment has come to light since the fourth edition of this work appeared in 2003. Molecular characteristics of these diseases that have major impact on prognosis and, sometimes, choice of treatment have been identi fi ed with ever-increasing frequency. In the fourth edition, imatinib was only brie fl y mentioned, and agents such as newer thymidine kinase inhibitors, lenalidomide, and bortezomib do not even appear in the index.